Spark hemophilia B gene therapy clears another early test – FierceBiotech
FierceBiotech |
Spark hemophilia B gene therapy clears another early test
FierceBiotech Spark Therapeutics has posted fresh data from a phase 1/2 trial of its hemophilia B gene therapy, SPK-9001. The data suggest Spark's tapering courses of steroids successfully arrested the factor IX (FIX) declines seen in two patients who appeared to … Spark carefully records a safe step forward for closely-watched hemophilia gene therapy Spark Therapeutics Presents Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and … |
